SIP
SLS icon

Stoneridge Investment Partners’s SELLAS Life Sciences SLS Stock Holding History

Stoneridge Investment Partners’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,287
Closed -$86K – 186
2026
Q1 		$86K Sell
20,287
-41,040
-67% -$184K 0.06% 120
2025
Q4 		$231K Buy
61,327
+7,618
+14% +$14.8K 0.16% 94
2025
Q3 		$86K Buy
+53,709
New +$95.7K 0.06% 115

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stoneridge Investment Partners's SLS Position: Q2 2026 in Review

Stoneridge Investment Partners sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 20,287 shares — an estimated $86K sold.

Stoneridge Investment Partners first reported a position in SLS in Q3 2025 and held it in 3 quarters. The position peaked at $231K in Q4 2025. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Stoneridge Investment Partners reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Stoneridge Investment Partners sold 20,287 SELLAS Life Sciences shares in Q2 2026, an estimated $86K.
  • Stoneridge Investment Partners first reported a position in SELLAS Life Sciences in Q3 2025 and held it in 3 quarters.
  • Stoneridge Investment Partners's SELLAS Life Sciences position peaked at $231K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.